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Abstract
Background: The national Cancer Reform Strategy recommends delivering care closer to home whenever
possible. Cancer drug treatment has traditionally been administered to patients in specialist hospital-based
facilities. Technological developments mean that nowadays, most treatment can be delivered in the out-patient
setting. Increasing demand, care quality improvements and patient choice have stimulated interest in delivering
some treatment to patients in the community, however, formal evaluation of delivering cancer treatment in
different community settings is lacking. This randomised trial compares delivery of cancer treatment in the
hospital with delivery in two different community settings: the patient’s home and general practice (GP)
surgeries.
Methods/design: Patients due to receive a minimum 12 week course of standard intravenous cancer treatment at
two hospitals in the Anglia Cancer Network are randomised on a 1:1:1 basis to receive treatment in the hospital
day unit (control arm), or their own home, or their choice of one of three neighbouring GP surgeries. Overall
patient care, treatment prescribing and clinical review is undertaken according to standard local practice. All
treatment is dispensed by the local hospital pharmacy and treatment is delivered by the hospital chemotherapy
nurses. At four time points during the 12 week study period, information is collected from patients, nursing staff,
primary and secondary care teams to address the primary end point, patient-perceived benefits (using the
emotional function domain of the EORTC QLQC30 patient questionnaire), as well as secondary end points: patient
satisfaction, safety and health economics.
Discussion: The Outreach trial is the first randomised controlled trial conducted which compares delivery of out-
patient based intravenous cancer treatment in two different community settings with standard hospital based
treatment. Results of this study may better inform all key stakeholders regarding potential costs and benefits of
transferring clinical services from hospital to the community.
Trial registration number: ISRCTN: ISRCTN66219681
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In the last 10 years since the Calman-Hine report [1],
cancer patient care in the United Kingdom has been
reorganised to deliver treatment within cancer centres
and cancer units within cancer service networks.
Patients benefit by accessing specialised staff, equipment
and treatment at the centre, while local cancer units
provide treatment for common conditions, but the qual-
ity of care received is systematised across large geogra-
phical areas. During these years, cancer incidence has
been rising in an ageing UK population, while develop-
ments in diagnosis and therapeutics alongside increasing
patient expectations mean that more patients than ever
before are being referred for cancer drug treatment.
Oncology specialist services have adapted to meet
increasing demand by delivering most drug treatments
in purpose-built day units. However, capacity pressures
are potentially driving down efficiency and risking main-
tenance of quality standards. The UK Government
White Paper, ‘Our health, our care, our say’ [2], pro-
motes patient choice and transfer of services closer to
people’s homes. Treatment for cancer patients in their
own homes is well established in the private sector, but
community treatment has been less extensively explored
within the National Health Service. Few formal studies
have been undertaken to evaluate the services that do
exist.
Most reports in the literature have concentrated on
evaluating delivery of cancer treatment in the home.
These suggest that home care is safe, while patients may
experience reduced side effects [3-5] and compliance
rates may improve [6,7]. The cost of delivering treat-
ment at home is poorly understood: some reports sug-
gesting the possibility of cost savings [8-10], while
others report home delivery to be more expensive
[6,11]. Private providers are keen to work with the
health service to deliver treatment in the community,
but concerns regarding clinical governance and cost-
effectiveness have been raised [12,13]. With few excep-
tions [12], most published studies are small and out-
dated.
Community treatment models other than homecare
already exist in the UK and include roving chemother-
apy delivery buses as well as satellite units in commu-
nity settings akin to models already established in other
specialities such as cardiology and diabetes, where hos-
pital teams visit GP surgeries on a regular basis. The
Department of Health has given a clear steer to encou-
rage commissioning of care closer to home despite a
lack of quality data to justify this recommendation [14].
The OUTREACH study aims to address the patient ben-
efits and costs associated with delivering treatment in
two different community settings compared with
standard hospital-based treatment, in order to better
inform future commissioning decisions.
Methods/design
Study Hypothesis
The primary hypothesis is that community-based che-
motherapy (whether at home or in a GP surgery) offers
patients improved quality of care compared with stan-
dard hospital-based treatment: patient perceived benefit
is thus the primary end point. The study aims to com-
pare delivery of systemic cancer therapy in three differ-
ent settings: hospital day unit, patient’sh o m ea n d
Outreach GP surgery, by means of a randomised con-
trolled trial.
Primary Aim
Patient perceived benefit, as measured quantitatively by
the emotional function domain of the EORTC QLQ-
C30 quality of life questionnaire.
Secondary Aims
1) Other patient benefits identified using the Hospital
Anxiety and Depression score, EQ-5D (EuroQol) and a
specifically designed patient satisfaction questionnaire.
2) Qualitative assessment of the experience of treat-
ment delivered in the three different locations, using
semi-structured interviews of patients, their carers
(where appropriate), and other health care professionals
(doctors, nurses and hospital managers either directly or
indirectly associated with this study).
3) Impact on costs and cost-effectiveness of treatment
delivered in the three different locations. It will evaluate
whether community care is cost-effective by measuring
the costs and benefits to the NHS and to patients.
4) Patient safety, determined by the number of adverse
and serious adverse events.
5) Compliance with treatment delivered in the differ-
ent locations.
6) Assessment of reasons why patients decline to take
part in the study.
Ethical approval
The protocol has research ethics committee approval
from the Cambridgeshire 2 Research Ethics Committee
and site specific assessment approval for each site
involved in the study.
Trial design and randomisation (Figure 1)
This is a prospective, randomised, controlled clinical
trial conducted at two neighbouring Trusts in the Anglia
Cancer Network: Addenbrooke’sH o s p i t a l( C U H )a n d
West Suffolk Hospital (WSH). Patients meeting the
defined eligibility criteria are invited to take part in the
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Page 2 of 10study prior to or during their planned cancer treatment.
All patients taking part provide written informed con-
sent. Patients are randomised on a 1:1:1 basis to one of
3 arms: treatment delivered in the hospital out-patient
and day unit environment (control arm A), treatment
delivered at home (arm B) or treatment delivered in a
GP surgery (arm C) using the method of minimisation
with a random element to the assignment. Randomisa-
tion is performed centrally by statisticians located sepa-
rately from trial recruitment and co-ordination and
without knowledge of patients or their characteristics.
In the minimisation procedure the patients are strati-
fied by centre (CUH or WSH), by treatment intent
(cure, palliation in terms of disease control and life pro-
longation, or supportive care aimed at symptom con-
trol), ECOG performance status (PS 0, 1 or 2), gender,
and prior cancer drug treatment (yes or no).
Study duration
The study period is defined as being 12 weeks on a par-
ticular course of treatment. Where patients continue
treatment beyond 12 weeks, those being treated at home
c a nc o n t i n u et od os o .H o w e v e r ,i ft h e yp r e f e rt ob e
treated in hospital they can transfer. Those patients ran-
domised to hospital treatment cannot cross over to
treatment in the community, since community-based
Randomise
Stratification: Hospital (CUH or WSH); treatment intent (cure, palliation, supportive care),
performance status (ECOG PS 0, 1, or 2), gender and prior cancer drug treatment (yes, or 
no)
Treatment at 
home
Treatment at
Outreach 
surgery
Treatment at 
hospital 
(control arm)
Patient fulfils eligibility criteria
Assess for patient quality of life measures, health-economics and safety
Figure 1 Trial design.
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ping treatment earlier than 12 weeks are not replaced in
the study, but the reason for stopping is noted. They are
included for the collection of study outcomes at 12
weeks, since analysis is on an intention-to-treat basis.
Eligibility
Cancer patients over 18 years of age being treated at
either CUH or WSH with standard infusions of under 4
hours duration and living within a 30 minute drive of
either hospital will be offered entry to this study. Eligible
patients must give written informed consent and be
about to commence a course of treatment planned to
last a minimum of 12 weeks, or have already com-
menced a course of treatment which is planned to con-
tinue for a minimum of 12 further weeks. The course of
treatment may be aimed at cure, palliation (disease con-
trol and life prolongation) or supportive care (symptom
control). Patients need to have hot and cold running
water in the home, an indoor toilet and a working tele-
phone. Patients must be ECOG performance status < 2,
or if ECOG PS 2, there must be a second individual liv-
ing in the home who functions as a carer.
Patients with life expectancy under 6 months or those
dependent on hospital transport are excluded. Other
exclusion criteria are: any patient receiving an unli-
censed cancer drug treatment as part of a clinical trial
where the drug is defined as an Investigational Medic-
inal Product unless the trial itself has received ethics
and R&D approval to be conducted in designated com-
munity settings used in the Outreach trial: patients with
language barriers or communication difficulties whose
safety might potentially be comprised by entry into this
trial: any patient where in the opinion of the Investiga-
tor entry into this trial would give cause for concern
regarding patient or staff safety.
Patient registration and randomisation
Eligible patients are registered with and randomised by
the Outreach Trial Co-ordinator, at the Cambridge Can-
cer Trials Centre (CCTC), CUH. Eligible patients are
allocated a unique trial number and the treatment loca-
tion defined. Registration and randomisation is underta-
ken by fax or email and the randomisation outcome
information provided to the Investigator by return,
within 24 hours. The Investigator is responsible for
organising the patient’s treatment and follow-up.
Study interventions
The Investigator has primary responsibility for the wel-
fare of the patient for the duration of the study, whether
receiving treatment in hospital, at home or in the GP
surgery. Patient treatment is governed by a single set of
standard operating procedures in use at CUH, WSH
(and the GP surgeries involved in this study.
The Investigator is responsible for prescribing all
treatment for trial patients, but can delegate this task to
a member of his or her junior staff, as is standard clini-
cal practice.
The treatment study period for this trial is 12 weeks,
since most treatments are expected to be prescribed for
at least this period of time. All planned treatment for a
study patient will be delivered in the location to which
the patient is randomised. Treatment of patients within
the community may be aborted and transferred to hos-
pital in the event of significant problematic drug-related
toxicities, occurrence of a serious adverse event (SAE),
on request by the patient, or following discussion
between the community chemotherapy nurse and the
Investigator who may feel it is in the patient’s best inter-
est to do so. The Investigator will review the patient in
clinic prior to study entry and on completion of the
study (whether at 12 weeks, or sooner in the case of
early withdrawal). For patients continuing treatment
beyond 12 weeks, the Investigator will review the patient
on completion of the planned treatment or at 24 weeks,
whichever is sooner.
All anticancer treatment and other prescribed drugs
are dispensed by the oncology pharmacists in the
respective hospitals, according to local policies. On the
designated day, prescribed drugs for patients receiving
treatment in the community are dispensed and placed
with a copy of the patient prescription sheet in a desig-
nated box, ready for collection by the community che-
m o t h e r a p yn u r s ef r o mt h eo n c o l o g yp h a r m a c ya ta
previously arranged time. The prescription sheet copy is
returned to the oncology pharmacy within 48 hours of
treatment.
Treatment plan
The location of treatment delivery is decided at the
point of trial entry. Once a patient had been randomised
to a treatment location, the Investigator will define the
treatment plan for the duration of the study period.
Treatment will commence within 28 days of randomisa-
tion. A written summary of the treatment plan and
emergency contact details will be provided to the
patient. In all cases, the Investigator will prescribe treat-
ment according to standard local practice.
For hospital-treated patients, all routine investigations
and clinic appointments will be arranged according to
standard clinical practice. For community-treated
patients, the clinician will establish, with the community
chemotherapy nurses, the treatment and follow-up
arrangements for the patient for the duration of the
study. This includes scheduled treatment times, need for
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until the end of the study period.
The chemotherapy nurses in hospital or the commu-
nity will liaise with the Investigator to ensure the treat-
ment plan for the patient is adhered to. They will
document any deviations from the initial treatment plan
and reasons for deviation. They liaise directly with the
Investigator (or a member of his/her team) regarding
any issues related to the patient’s treatment. During the
study, patients are asked to use the emergency contact
details provided should problems of any kind arise.
Study patient groups
Hospital (control) arm
Patients receiving treatment in hospital have their treat-
ment delivered by appropriately trained chemotherapy
nurses as per standard policies and procedures in each
hospital.
GP surgery arm
Patients allocated treatmenta taG Ps u r g e r ya r eg i v e n
the choice of being treated in one of 3 local surgeries in
the area: The Christmas Maltings and Clements Surgery,
Haverhill, East Barnwell Health Centre, Cambridge, or
the Swan Surgery, Bury St Edmunds. All GP surgeries
have generous, free parking facilities and their locations
provide convenience for patients attending CUH and
WSH. Patients entering this study do not have to be
registered with these GP surgeries. All patients receive
visual and written information regarding the geography
of the surgeries as part of the invitation to take part in
the trial to assist with their choice of surgery. Following
allocation to this arm of the trial, a more detailed infor-
mation leaflet and map describing the treatment venue
is provided.
Home arm
Delivery of treatment in the home is delegated to
trained chemotherapy nurses employed by CUH and
WSH
Patient assessments
Blood tests, radiological investigations and clinician
reviews are undertaken on patients in all arms of the
study, as per standard practice defined for each disease
site and treatment regimen being used. Patients receiv-
ing treatment in the community have blood taken in the
community and sent to the hospital laboratory so that
the result is available to the Investigator on the day that
treatment is due.
Prior to each course of treatment, patients receiving
treatment in hospital are seen by the Investigator or
delegated team member as per standard clinical practice,
before proceeding with treatment. Patients receiving
treatment in the community are assessed by the com-
munity chemotherapy nurse, who liaises with the
prescribing clinician before proceeding with each course
of treatment. Patients on any arm of the study can be
referred for non-routine clinical review on request by
another health care professional or on request by the
patient. The frequency and reasons for extra clinical
reviews will be monitored as part of the study, as part
of adverse event reporting.
Concomitant medication
Patients may receive all concomitant therapy deemed to
provide adequate supportive care. Since this trial is not
directly interested in treatment per se, concomitant
medications will not be systematically recorded. How-
ever, information about ongoing treatment at the time
of study entry and changes in treatment during the
course of the study will be recorded by the patient in
the Client Service Receipt Inventory (CSRI). In addition,
records of drugs prescribed by the hospital and the
patient’s own GP will be obtained.
Recording and collection of data
Upon randomisation of an individual patient, a pack
containing specifically designed data collection forms,
questionnaires and diaries is provided to the Investiga-
tor. The forms allow collection of essential information
required for the study at each predefined trial data col-
lection point. The study has four mandatory and 1
optional data collection point. Mandatory data collection
points are baseline (at the start of study treatment), then
approximately 4 weeks, 8 weeks and 12 weeks after
commencing treatment. For patients continuing treat-
ment beyond 12 weeks, there is an optional data collec-
tion point at 24 weeks or on stopping treatment,
whichever occurs sooner. The baseline, 12 week and 24
week data collection visits take place at hospital. On
these occasions, study forms will be completed by the
Investigator or a member of his/her team, which may
include a specialist or research nurse/practitioner.
Patient questionnaires and diaries are given to the
patient and/or collected from the patient as appropriate
at these visits.
In order to allow for different treatment schedules, the
second and third data collection points may be flexible
to within 1 week either side of the planned 4 and 8
week time points. For patients having treatment in hos-
pital, on these occasions, forms are completed by the
Investigator or a member of his/her team, which may
include a specialist or research nurse/practitioner.
Patient questionnaires are given to and collected from
the patient as appropriate at these visits. For patients
having treatment in the community, these study forms
are completed by the community chemotherapy nurse.
Patient questionnaires are given to and collected from
the patient as appropriate at these visits.
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forms and questionnaires are returned to the Outreach
Trial Coordinator, who is responsible for creating and
completing the unique patient Case Report Forms
(CRF).
Patients randomised to receive treatment in either
c o m m u n i t ys e t t i n gm a yb et r a n s f e r r e da ta n yt i m et o
continue treatment in hospital, and the date and reason
f o rt r a n s f e rw i l lb ed o c u m e n t e d .T r a n s f e ro fc a r et ot h e
hospital constitutes a serious adverse event (SAE) and
withdrawal from the trial. Patients randomised to
receive treatment in hospital may not be transferred to
either location in the community, since this is not stan-
dard clinical practice locally.
Study procedures
The study procedures are summarised in Table 1.
Outcome measures
Study end points
1) Primary end point: Patient perceived benefit
Patient perceived benefit is quantitatively measured by
determining overall quality of life using the EORTC
QLQC30 instrument. The mean quality of life emotional
function score will be compared between study popula-
tions, since this domain might be considered to best
reflect the levels of anxiety and satisfaction felt by
patients taking part in this study.
The QLQC30 questionnaire will be administered prior
to randomisation, at 4 weeks, 8 weeks and 12 weeks.
Where patients continued to receive the same treatment
beyond 12 weeks, they are asked to complete a similar
questionnaire once more when their treatment stopped,
or at 24 weeks, whichever is sooner. Where a carer is
identified, the carer is also asked to complete EORTC
QLQC30 questionnaire at each time point.
2) Secondary end points
i) Additional patient perceived benefits
Additional comparisons of global quality of life, anxiety
and overall satisfaction with treatment received are
made by asking patients to complete three additional
questionnaires, as follows:
- The EQ-5D (EuroQol) instrument
- The Hospital Anxiety and Depression (HAD)
questionnaire
- A specifically designed patient satisfaction
questionnaire
Each questionnaire is completed prior to randomisa-
tion, at 4 weeks, 8 weeks and 12 weeks. Where patients
continue to receive the same treatment beyond 12
weeks, they are asked to complete a similar set of ques-
tionnaires when their treatment stopped or at 24 weeks,
whichever is sooner. Where a carer is identified, the
carer was also asked to complete the three question-
naires at each time point.
ii) Semi-quantitative interviews
To triangulate the quantitative patient data, prior to
commencing treatment and after 12 weeks, one in every
10 patients (and main carer if available) is randomly
selected in each arm, during the main randomisation,
Table 1 Study measures and timing
Data point 1: Baseline,
prior to commencing
treatment
Data point 2: 4**
weeks into
treatment
Data point 3: 8**
weeks into
treatment
Data point 4: 12
weeks into
treatment
Data point 5: 24***
weeks into
treatment
Clinic Review* x x X
P S x xxxX
Weight x x x x
Blood tests* x
Radiology* x
EORTC QLQC30. x x x x X
HAD, EQ-5D and Patient
Satisfaction
Questionnaire
x xxxX
CSRI Completion x x
Patient Diary for AE
Recording
x xxxX
Semi-Structured
Interview
x(1 in 10 patients) x
*Clinic review, blood tests and radiological investigations will be carried out according to standard clinical practice at baseline and during the study period.
** +/- 1 Week
*** For patients whose treatment continues beyond 12 weeks, patients will complete a further set of trial assessments when their treatment stops or at 24
weeks, whichever is sooner. This data point is optional.
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ask specifically about their experiences relating to the
treatment received. Since the perceptions and experi-
ence of staff responsible for the service is also consid-
ered to be important, 12 clinicians responsible for
patients entering the trial (at least 2 from WSH, the
remainder from CUH), 1 doctors from each GP Surgery,
6 treatment delivery nurses (2 from WSH, 4 from CUH)
and 2 senior level Oncology Managers at each hospital
are being interviewed prior to and on completion of the
study. All interviews are recorded, transcribed and sub-
sequently analysed using a Framework approach.
iii) Service use and cost data
Service use and cost data relating to patients, the NHS
and society as a whole, is collected and compared for all
arms of the study. Use of the specific cancer drug treat-
ments is centrally recorded. Other service use data was
collected using an adapted version of the CSRI [15]. The
CSRI has been used in around 200 health economic stu-
dies of health and social care interventions in the UK
and internationally. Service use information is typically
provided by the patient and/or family members (supple-
mented where possible with administrative data from
providers) and the objective is to allow comprehensive
costs to be generated.
By means of the adapted CSRI, patients are asked to
provide information on a range of services used, taking
place at Baseline and at 12 weeks. Services include con-
tacts with staff directly related to the delivery of cancer
care (oncologists, nursing staff, hospital-based pharma-
cists, etc), plus other healthcare professionals (GPs, pri-
mary care nurses, psychologists, etc), and social care
professionals. Time spent in hospital (overnight stays
plus day-patient attendances) is recorded. In addition,
time per week spent by family/friends providing care
(broken down into specific tasks) to the patient because
of their condition is recorded.
A key cost is thought to be related to time spent tra-
velling by patients and/or staff, to receive or deliver
treatment. Patients are asked to state where contacts
take place and time spent travelling to use them and
also mode of travel. Many patients are accompanied and
the CSRI also records information on this. A further
section in the CSRI records time taken off work by
patients and family members specifically because of the
condition and treatment.
Data is also collected from the chemotherapy nurses.
They are asked to document all scheduled and unsched-
uled contact with their patients as well as working
hours relating to treatment of trial patients.
Unit costs are attached to the service use data to pro-
duce service costs for each patient in the study. The
costs of delivering treatment in hospital, GP surgeries
and at home are derived from information on salary
costs, administrative and capital overheads, and drug
costs. The unit costs of other services are obtained from
nationally applicable data [16]. The cost of a home care
worker is used to value care provided by family mem-
bers/friends. Travel time costs are estimated using wage
rates for those in employment and a proportion of this
for those who are not in work.
Costs are compared between the three groups using
bootstrap methods to account for the likely non-normal
distribution of the data. Cost-effectiveness is assessed by
combining service cost data with the primary outcome
measure (QLQ-C30) and also Quality Adjusted Life
Year (QALYs) generated from the EQ-5D [17]. Two-
w a yc o m p a r i s o n sa r em a d eb e t w e e nt h eg r o u p s .I fo n e
group has lower costs and better outcome over another
then it would be dominant. If costs are higher and out-
come better then incremental cost-effectiveness ratios
would be constructed which will show the extra cost
incurred to achieve an extra unit of outcome. To
address uncertainty in the cost and outcome differences,
cost-effectiveness acceptability curves are used which
will show the probability that one option is more cost-
effective than another for different values placed on a
unit improvement in outcome.
iv) Patient safety
C U Ha n dW S Hh a v ei np l a c eac o m p r e h e n s i v es e to f
policies and procedures governing community-based
care. Specifically for cancer, the Cancer Treatment in
the Community (CTC) policy identifies low risk patients
and low risk treatments usually offered to patients in
the hospital out-patient and day unit facilities which are
potentially suitable for delivery in the community (Table
1). In addition, the CTC policy describes a clinical gov-
ernance framework for ensuring patient safety in the
community, reflecting standard policies and procedures
adhered to when delivering cancer treatment in hospital.
To be considered for this trial, both the patients and the
treatment being offered are required to meet the criteria
listed in the CTC Policy.
The treatments given to patients taking part in this
trial are by definition those which are well established,
with an excellent safety record. Our hypothesis is that
patients would not be adversely affected or harmed by
receiving treatment in the community. Appropriate
safety measures and procedures are in place for commu-
nity treatment, to provide a safe environment considered
to be equivalent to the hospital setting.
Patient safety will be evaluated by recording the num-
ber of adverse and serious adverse events which occur
during the study period (see safety procedures).
v) Compliance with treatment delivered in the different
locations
Patient compliance with their treatment is monitored as
per standard local practice.
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Page 7 of 10vi) Non-participation in study
The reasons why patients might decide not to take part
in this study are of considerable interest. A short, anon-
ymised questionnaire is offered to any patient who
declines to take part. The patients are under no obliga-
tion to complete the questionnaire. Exploration of the
responses on the returned forms offers insight into
patient concerns regarding such delivery options, and
therefore an indicator as to the likely take-up of future
community chemotherapy delivery programmes.
In addition, all patients are monitored for symptom
control, tumour response and overall survival according
to standard clinical practice.
vii) Impact of treatment on local GP resources
Once a patient has completed the trial, a letter is sent to
the patient’s own GP requesting review of the patient
notes held at the local GP surgery to document: the
number of occasions the patient contacted his or her
GP surgery during the trial period; what type of surgery
staff were involved on each occasion (e.g. GP, nurse,
other); the nature of those contacts, by classifying them
as being related to a) cancer treatment, b) other need
for treatment of any kind, c) support services, d) advice,
or e) other. In addition, a summary print-out of all pre-
scriptions is requested. The GPs receive a small remu-
neration for providing this information.
Safety procedures
Adverse events
For the purposes of this trial, an adverse event (AE) is
defined as:
- any unscheduled contact (e.g. phone calls, face-face
visits etc) made by the patient, or carer to the outpatient
or community treatment nurse, Investigator or member
of his/her team, GP, or other support staff in relation to
their current course of treatment.
- any unscheduled contact (e.g. phone calls, face-face
visits etc) made by the out-patient, or community treat-
ment nurse to the Investigator or member of his/her
team, GP, or other support staff relating to the manage-
ment of the patient receiving treatment.
To ensure accurate collection of trial-specific AEs,
trial patients and treatment delivery nurses are issued
with a purpose-designed diary in which to record all
occasions when unscheduled contact is made. Specific
information regarding contact is also requested. All AEs
which occur from randomisation until the final trial visit
are recorded. Specific information to be recorded in the
diary regarding AEs includes the date and time of
occurrence, main reason for making contact, with whom
contact is made and outcome.
Serious adverse events
For the purposes of this trial, a serious adverse event
(SAE) was defined as including any event which:
- results in death, regardless of cause.
- is life-threatening (immediate risk of death).
- requires hospitalisation or prolongation of existing
hospitalisation, excluding those planned for cancer treat-
ment, disease related procedures, or placement of an
indwelling catheter, unless associated with other serious
events.
- results in persistent or significant disability/
incapacity.
- consists of a congenital abnormality of birth defect.
- involves grade 3 or 4 (severe or life threatening)
drug-related toxicities.
- results in the patient’s treatment being switched
from the community to hospital-based treatment.
This trial is not evaluating treatment per se,b u tt h e
venue of treatment delivery. Thus, reporting of drug-
related AEs is limited to reporting of severe or life
threatening toxicities, according to National Cancer
Institute, Common Toxicity Criteria.
All SAEs which occur from randomisation until the
final trial visit are recorded. All SAEs are reported to
the CCTC immediately, by completing an SAE form,
and assessed by the Chief Investigator. Autopsy data,
where available, for deaths occurring from randomisa-
tion until 28 days after the last planned treatment
administration are provided to the CCTC.
The relationship of SAEs to treatment delivery venue
is assessed using the following definitions:
- Not related - The adverse event would definitely
have occurred whatever the venue
- Unlikely to be related - The adverse event would
probably have occurred whatever the venue
- Possibly related - The adverse event had a timely
relationship to treatment venue. However, a potential
alternative aetiology existed.
-P r o b a b l yr e l a t e d-T h ea d v e r s ee v e n th a dat i m e l y
relationship to treatment venue and a potential alterna-
tive aetiology was not apparent.
- Definitely related - The adverse event had a timely
relationship to treatment venue and a potential alterna-
tive aetiology was not apparent. Upon switching treat-
ment to hospital-based delivery, the adverse event would
definitely not occur.
’Unlikely’ and ‘Not related’ are considered not treat-
ment venue related. ‘Definitely’, ‘Probably’ and ‘Possibly’
are considered treatment venue related.
In the case of an SAE, the subject will be followed up
until recovery or stabilisation. The Investigator will take
all measures necessary to resolve any SAE.
Sample size
The EORTC QLQC30 questionnaire is a well validated
instrument; this has been in widespread use since 1993
and is frequently used to assess quality of life of cancer
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Page 8 of 10patients in clinical trials. It comprises 30 questions
representing various dimensions of quality of life. Of the
5 functional dimensions, emotional function might be
considered to best reflect the levels of anxiety and satis-
faction felt by patients taking part in this study. Using
data on quality of life dimension mean scores deter-
mined by researchers interested in interpreting the
results of the QLQC30 questionnaire, the standard
deviation of the mean quality of life emotional function
score for a large group of heterogeneous cancer patients
is determined to be 24 [18,19].
With 130 patients randomised per arm, there is 80%
power to detect a 10-point difference in mean QLQC30
score between any two study populations, at the 5%
level of significance assuming a standard deviation 24.
This allows for up to 30% of patients not providing
information on the primary outcome, for reasons
including withdrawal and non-completion of question-
naire. There is also 90% power to detect a 10-point dif-
f e r e n c eb e t w e e nt h eh o m ea n dG Ps u r g e r ya r m s
combined versus hospital using data from all three arms.
Statistical Analysis
The primary analysis time-point is 12 weeks. The pri-
mary contrast is between home and GP surgery arms
combined, versus hospital arm. Binary outcomes will be
analysed using logistic regression. Continuous outcomes
will be analysed using linear regression adjusting for
randomisation stratifiers and the pre-randomisation
baseline of the outcome in order to improve precision
of the estimated intervention effects. Participants with
v a l i dd a t aa tf o l l o w - u pb u tw i t hm i s s i n gd a t aa tb a s e l i n e
will be retained in the analysis by using the missing
indicator method [20]. For measures repeated over time,
linear mixed models will be used to analyse data from
all time-points together, to assess for any patterns
between study arms. The level of missing data will be
compared by study arm. A logistic regression model will
be used to examine whether baseline factors or inter-
mediate study measures predict dropout by 12 weeks.
With sufficient 12-week data, the impact of missing data
on the main outcomes will be assessed using best and
worst case sensitivity analyses, using multiple imputation
[21], or otherwise using the linear mixed effects model
with the available 4-week and 8-week data to model the
12-week effect from the trend in the outcome over time
in each arm. Further analyses will include comparisons
between pairs of arms, analyses at time-points and sub-
group analyses, with subgroups defined by treatment
intent and hospital.
Trial organisation and management
The trial has a Trial Management Group (TMG), a
Steering Committee and an independent data and safety
monitoring committee (IDSMC). The TMG meets
monthly. The IDSMC advises the Steering Committee
regarding any evidence or reason why the study should
be amended or terminated based on the recruitment
rates or safety. The Steering Committee report their
findings to the TMG.
The initial meeting of the ISDMC will take place 6
months after commencing recruitment, to assess safety
of the study and recruitment efficiency. The IDSMC will
then meet annually to monitor recruitment to the trial,
protocol compliance as well as toxicity, serious adverse
events and outcome.
Discussion
Delivery of treatment in the community is of interest to
the Department of Health, local commissioners and pro-
viders of health care, as well as to patients. Community
cancer treatment service models are currently being
established, but evidence of costs and benefits of these
services is lacking. The Outreach trial is the first rando-
mised trial undertaken in the UK to formally compare
delivery of cancer treatment in the community with tra-
ditional hospital treatment. The results of this study will
inform wider debate regarding implementation of these
services in the future.
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